Cancer researchers at the Stanford University School of Medicine have found in a study of mice that switching off a single malfunctioning gene halts the limitless division of tumour cells, and turns them back to the path of their own planned obsolescence.
Dr. Dean Felsher, Associate Professor of Medicine (oncology) and Pathology, says that the surprising possibility that a cell's own natural mechanism for ensuring its mortality may be used to vanquish tumours opens the door to a new approach to developing drugs to treat cancer patients.
Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors account for about 2.4% of all the tumor diagnosesandare most challenging due to their critically delicate location.
Advertisement
"Our research implies that by shutting off a critical cancer gene, tumour cells can realize that they are broken and restore this physiologic fail-safe program," said Felsher, the senior author of the study published online in the Proceedings of the National Academy of Sciences.
The gene that the researchers studied produces a protein called Myc (pronounced "mick"), which promotes cell division. A mutation of the gene causes cells to overproduce the protein, prompting perpetual cell division and tumour growth.
![Researchers Have Identified the Gene Involved in Breast Cancer]( "Researchers Have Identified the Gene Involved in Breast Cancer")
Researchers at the University of Michigan have identified a gene linked to the development of an aggressive form of breast cancer.
When the researchers turned off the mutated gene, they found that not only did uncontrolled cell division cease, but the cells also reactivated a normal physiological mechanism, called senescence, which makes it possible for a cell to eventually die.
"What was unexpected was just the fact that cancer cells had retained the ability to undergo senescence at all," said Felsher.
The researchers worked with a series of mice engineered to have Myc-triggered cancers of either the liver, blood or bones, along with a specially constructed version of the Myc gene that they could switch off by feeding the mice antibiotics. When the mice were administered the drugs, the tumours ceased growing and then diminished, with some disappearing over the course of just a few days.
This is the first time that cancer researchers have explored the idea that senescence might play a key role in diminishing tumours; most of the previously conducted studies focused on reactivating tumour-suppressor genes, which are generally overcome by a proliferating cancer.
Dr. Felsher described senescence as acting like a fail-safe mechanism to stop cancer. When a cell detects a deleterious mutation, it launches the senescence process, resulting in the permanent loss of the cell's ability to proliferate, thus halting any cancer.
"In order to become tumour cells, those cells have to overcome senescence," said Dr. Chi-Hwa Wu, postdoctoral researcher in Felsher's lab and first author of the study.
Dr. Felsher considers it a cell version of the Jekyll and Hyde transformation.
"It's sort of like Mr. Hyde realizing that there's something wrong with him and then being able to put himself back into his normal state as Dr. Jekyll," he said.
The researchers are now planning to test how well the approach works in human cancer cells.
"And we're also trying to figure out what the mechanism is. What are the molecular mechanisms of this, so that we can figure out how to better treat cancer," Felsher said.
Source: ANI
LIN/B
Researchers Have Identified the Gene Involved in Breast Cancer
Researchers at the University of Michigan have identified a gene linked to the development of an aggressive form of breast cancer.
Advertisement
When the researchers turned off the mutated gene, they found that not only did uncontrolled cell division cease, but the cells also reactivated a normal physiological mechanism, called senescence, which makes it possible for a cell to eventually die.
"What was unexpected was just the fact that cancer cells had retained the ability to undergo senescence at all," said Felsher.
The researchers worked with a series of mice engineered to have Myc-triggered cancers of either the liver, blood or bones, along with a specially constructed version of the Myc gene that they could switch off by feeding the mice antibiotics. When the mice were administered the drugs, the tumours ceased growing and then diminished, with some disappearing over the course of just a few days.
This is the first time that cancer researchers have explored the idea that senescence might play a key role in diminishing tumours; most of the previously conducted studies focused on reactivating tumour-suppressor genes, which are generally overcome by a proliferating cancer.
Dr. Felsher described senescence as acting like a fail-safe mechanism to stop cancer. When a cell detects a deleterious mutation, it launches the senescence process, resulting in the permanent loss of the cell's ability to proliferate, thus halting any cancer.
"In order to become tumour cells, those cells have to overcome senescence," said Dr. Chi-Hwa Wu, postdoctoral researcher in Felsher's lab and first author of the study.
Dr. Felsher considers it a cell version of the Jekyll and Hyde transformation.
"It's sort of like Mr. Hyde realizing that there's something wrong with him and then being able to put himself back into his normal state as Dr. Jekyll," he said.
The researchers are now planning to test how well the approach works in human cancer cells.
"And we're also trying to figure out what the mechanism is. What are the molecular mechanisms of this, so that we can figure out how to better treat cancer," Felsher said.
Source: ANI
LIN/B
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Genetics & Stem Cells News
Relapsing-remitting multiple sclerosis has been successfully treated using autologous hematopoietic stem cell therapy.
Innovative discoveries in male hair loss research uncover uncommon genetic variants tied to it.
Researchers achieved a significant milestone in uncovering the genetic basis of dilated cardiomyopathy in Dobermanns.
Groundbreaking gene therapy for genetic beta thalassemia is now accessible as a treatment to a patient post-FDA approval.
Thymic stem cells actively participate in their environment by generating extracellular matrix proteins, essentially forming their own support system.
